Faculty Opinions recommendation of Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review.

Author(s):  
Roberto Arenas ◽  
Eder Rodrigo Juarez-Duran
PLoS ONE ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. e0218786 ◽  
Author(s):  
Carolina Rocio Santos ◽  
Felipe Francisco Tuon ◽  
Juliette Cieslinski ◽  
Regina Maia de Souza ◽  
Rui Imamura ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e045707
Author(s):  
Faheel Naeem ◽  
Keren Nathan ◽  
Jeffrey Chivinski ◽  
Taline Ekmekjian ◽  
Michael Libman ◽  
...  

IntroductionTreatment of cutaneous and mucosal leishmaniasis (CL and ML, respectively) must be individualised as there is no universal therapeutic approach. Intravenous liposomal amphotericin B (L-AmB) is an accessible and relatively safe treatment that has been increasingly used for the treatment of CL and ML. While several descriptive studies have been published on the efficacy and safety of L-AmB, there are no interventional studies. Moreover, the findings from published studies have not yet been integrated and synthesised. Therefore, we aim to evaluate and consolidate the descriptive evidence on the efficacy and the safety of Intravenous L-AmB treatment for CL and ML in both the New and Old World.Methods and analysesA systematic review of all relevant study types with no restriction on date or language of publication will be conducted. Online databases including MEDLINE, The Cochrane Library, EMBASE, EBSCO, Scopus, Ovid and WHO databases were searched on 3 April 2020. The search included all study types that assess Intravenous L-AmB treatment for CL and ML in humans. The Population, Intervention, Comparison, Outcome and Study Design strategy and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be used to determine which studies will be selected for final inclusion. The quality of included case series and case reports will be assessed using modified quality assessment tools. A narrative synthesis of the findings will be provided and the primary outcome and secondary outcome of interest, response rate and adverse events rate, respectively, and the 95% CI will be ascertained. Estimates from individual studies will be pooled using random-effects model.Ethics and disseminationThis systematic review does not require formal ethical approval since no primary data will be collected. Findings will be disseminated through a peer-reviewed publication and relevant conferences.PROSPERO registration numberCRD42020173440.


2018 ◽  
Vol 56 (1) ◽  
pp. 84-86
Author(s):  
Magali Garcia ◽  
Gwénaël Le Moal ◽  
Jacques Cadranel ◽  
France Roblot ◽  
Cendrine Godet

2017 ◽  
Vol 182 (7-8) ◽  
pp. 709-713 ◽  
Author(s):  
Cendrine Godet ◽  
Estelle Cateau ◽  
Blandine Rammaert ◽  
Marine Grosset ◽  
Gwenaël Le Moal ◽  
...  

Mycoses ◽  
2015 ◽  
Vol 58 (3) ◽  
pp. 173-180 ◽  
Author(s):  
Cendrine Godet ◽  
Véronique Goudet ◽  
François Laurent ◽  
Gwenaël Le Moal ◽  
Valérie Gounant ◽  
...  

2019 ◽  
Vol 58 (7) ◽  
pp. e137-e138
Author(s):  
Paula Aguayo‐Carreras ◽  
Carlos Cuenca‐Barrales ◽  
Israel Perez‐López ◽  
Ricardo Ruiz‐Villaverde ◽  
Jesus Tercedor‐Sanchez

Sign in / Sign up

Export Citation Format

Share Document